Trial reportBMC oral health2014
Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial.
Trial report in BMC oral health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Effect of a Short-Term Intervention withInternational journal of environmental research and public health · 2022Trial
- Trial
- Impact of the food grade heat-killed probiotic and postbiotic oral lozenges in oral hygiene.Aging · 2022Trial
- Review
- Natural Compounds in Oral Microbiota Modulation and Caries Prevention: A Systematic Review.Dentistry journal · 2025Review
- The strategic role of biotics in dental caries prevention: A scoping review.Food science & nutrition · 2024Article
- A Color Indicator Based on 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) and a Biodegradable Poly(ester amide) for Detecting Bacterial Contamination.International journal of molecular sciences · 2024Article
- Effect of Probiotic Supplements on the Oral Microbiota-A Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- Preparation and In Vitro Characterization ofJournal of functional biomaterials · 2024Article
- The Oral Microbiota in Valvular Heart Disease: Current Knowledge and Future Directions.Life (Basel, Switzerland) · 2023Review
- A comprehensive review of the application of probiotics and postbiotics in oral health.Frontiers in cellular and infection microbiology · 2023Review
- From Mouth to Muscle: Exploring the Potential Relationship between the Oral Microbiome and Cancer-Related Cachexia.Microorganisms · 2022Review
- Lactobacillus cell envelope-coated nanoparticles for antibiotic delivery against cariogenic biofilm and dental caries.Journal of nanobiotechnology · 2022Article
- Probiotics: Dawn of a New Era in Dental Caries Management.Journal of pharmacy & bioallied sciences · 2022Review
- Effects of green tea extract epigallocatechin-3-gallate (EGCG) on oral disease-associated microbes: a review.Journal of oral microbiology · 2022Review
- Ligilactobacillus salivarius functionalities, applications, and manufacturing challenges.Applied microbiology and biotechnology · 2022Review
- Assessing the drug resistance profiles of oral probiotic lozenges.Journal of oral microbiology · 2022Article
- Effect of Probiotic Lactobacillus salivarius on Peri-Implantitis Pathogenic Bacteria: An In Vitro Study.Cureus · 2021Article
- Protective Action ofMaterials (Basel, Switzerland) · 2021Article
- A Review of the Role of Probiotic Supplementation in Dental Caries.Probiotics and antimicrobial proteins · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the effects of the lactic acid bacterium Lactobacillus salivarius on caries risk factors.
methodsThe study was performed in 64 healthy volunteers to evaluate the effects of L. salivarius-containing tablets on caries risk factors. The participants were divided randomly into four groups, and took tablets containing L. salivarius WB21, L. salivarius TI 2711, Ovalgen® DC (antibody against glucosyltransferase from Streptococcus mutans), or xylitol. Levels of mutans streptococci and lactobacilli, amount of salivary flow, salivary pH, and salivary buffering capacity were assessed before and after taking the tablets. Subsequently, a short-term administration trial using L. salivarius WB21-containing tablets was performed in eight healthy volunteers. The participants took L. salivarius WB21-containing tablets (2.0 × 10(9) colony forming units/day) for 2 weeks, and the numbers of mutans streptococci in saliva were counted.
resultsThe levels of mutans streptococci seemed to decrease in the L. salivarius WB21, TI 2711, and Ovalgen® DC groups compared to the xylitol group, with no significant differences between the groups. Lactobacilli levels significantly increased in the L. salivarius WB21 and TI 2711 groups compared to the other groups. Concerning salivary flow and salivary pH, no significant differences were observed between the groups. The salivary buffering capacity significantly increased in the L. salivarius TI 2711 group (P = 0.003) and Ovalgen® DC group (P = 0.002) compared to the xylitol group. The short-term administration trial showed that the L. salivarius WB21-containing tablets significantly decreased the number of mutans streptococci (P = 0.039).
conclusionL. salivarius-containing tablets were suggested to increase resistance to caries risk factors.
trial registrationUMIN000013160 (registration date: February 14, 2014).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.